# Thyr care<sup>®</sup>

Think Thyroid. Think Thyrocare.

November 27, 2020

To, National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai - 400 051

BSE Limited Phiroze Jeejeeboy Towers Dalal Street, Mumbai- 400 001

Dear Sirs,

# Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

--0--

Pursuant to Regulation 23 (9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are filing herewith Disclosure of Related Party Transactions during the half year ended on September 30, 2020 on a consolidated basis, in the format specified in the accounting standards, and the same is also available on the website of the Company viz, www.thyrocare.com.

Please take the same on record.

Yours Faithfully,

For Thyrocare Technologies Limited,

Ramjee Dorai Company Secretary and Compliance Officer



Thyrocare Technologies Limited

D-37/1, TTC MIDC, Turbhe, Navi Mumbai - 400 703, India (© 022- 3090 0000 / 4125 2525)
a enquiry@thyrocare.com () www.thyrocare.com

# Thyrocare Technologies Limited

Notes to the standalone financial statements

for the half year ended 30 September 2020

Currency: In crore of INR

#### **Related** parties

#### A. Details of related parties:

| Description of relationship   | Names of related parties   |
|---|--|
| Subsidiary  | Nueclear Healthcare Limited  |
| Associates  | Equinox Labs Private Limited   |
| Enterprise over which directors and their relatives exercise control or influence,<br>where transactions have taken place during the year | Thyrocare Gulf Laboratories WLL<br>Sumathi Healthcare Private Limited (Preiously known as Sumathi<br>Construction Pvt Ltd) |
| Key Management Personnel (KMP)  | Dr A Velumani, Managing Director<br>A Sundararaju, Director  |
|   |  |

#### B. Transactions with key management personnel

#### i. Key management personnel compensation

|               | Transactions for the half year ended 30 September 2020 | Balance outstanding |
|---------------|--|---------------------|
| Dr A Velumani | 0.00*  | 0.00*               |
| A Sundararaju | 0.25   | 0.04                |

\* Amount less than Rs. 0.01 crore

As the liabilities for defined benefit plans are provided on actuarial basis for the Company as a whole, the amount pertaining to key managerial personnel are not separately determined and hence not included in the above amounts.



C. Related party transaction other than those with key management personnel

|  | Transactions for the half year ended 30 September 2020 | Balance outstanding |
|--|--|---------------------|
| Lease Paid / payable                     |  |                     |
| Sumathi Healthcare Private Limited       | 0.16   |                     |
| Nueclear Healthcare Limited              | 0.20   |                     |
| Rent received / receivable               |  |                     |
| Nueclear Healthcare Limited              | 0.13   | -                   |
| Lease received / receivable              |  |                     |
| Nueclear Healthcare Limited              | 0.10   | -                   |
| Outlab processing charges paid / payable |  |                     |
| Equinox Labs Private Limited             |  | 0.03                |
| Revenue from operations                  |  |                     |
| Thyrocare Gulf Laboratories WLL          | 0.04   | 2.09                |
| Sumathi Memorial Trust                   | 0.04   | 0,02                |
| Repayment of loans by subsidiary         |  |                     |
| Nueclear Healthcare Limited              |  | 16.1:               |
| Interest received                        |  |                     |
| Nueclear Healthcare Limited              | 0.63   | 0.63                |
| Reimbursement of expenses (received)     |  |                     |
| Nueclear Healthcare Limited              | 0.26   | 0.05                |
| Reimbursement of expenses (paid)         |  |                     |
| Nueclear Healthcare Limited              | 0.18   | <u>.</u>            |
| Sumathi Healthcare Private Limited       | 0.22   | 0.1                 |
| Technical assistance fees income         |  |                     |
| Thyrocare Gulf Laboratories WLL          | 0.67   | 3.70                |
| Investment in equity instruments         |  |                     |
| Equinox Labs Private Limited             |  | 20.00               |
| Nueclear Healthcare Limited              |  | 150.3-              |
| Security deposit taken                   |  |                     |
| Nueclear Healthcare Limited              |  | 1.1:                |
| Security deposit given                   |  |                     |
| Nueclear Healthcare Limited              | -  | 0,19                |

#### Notes :

i. The key management personnel, or their related parties, hold position in other entities that result in them having control or significant influence over these entities. These entities transacted with the Company during the reporting period. The terms and conditions of the transactions with key management personnel and their related parties were no more favourable than those available, or those which might reasonably be expected to be available, in respect of similar transactions with non-key management personnel entities.



# Thyrocare Technologies Limited

# Notes to the consolidated financial statements

for the half year ended 30 Sep 2020

Currency : In crore of INR

# **Related** parties

| Description of relationship  | Names of related parties   |
|--|--|
| Associates   | Equinox Labs Private Limited   |
| Enterprise over which directors and their relatives exercise control or influence, where transactions have taken place during the year | Thyrocare Gulf Laboratories WLL<br>Sumathi Healthcare Private Limited * (Previously<br>known as Sumathi Construction Private Limited)<br>Pavilion Commercial Private Limited<br>Sumathi Memorial Trust |
| Key Management Personnel (KMP)   | Dr A Velumani, Managing Director<br>A Sundararaju, Director  |

# B. Transactions with key management personnel

## i. Key management personnel compensation

|               | Transaction value | Balance<br>outstanding |
|---------------|-------------------|------------------------|
|               | Half Year ended   | Half Year ended        |
|               | 30 Sep 2020       | 30 Sep 2020            |
| Dr A Velumani | 0.00*             | 0.00*                  |
| A Sundararaju | 0.25              | 0.04                   |

\* Amount less than Rs. 1 lakh

As the liabilities for defined benefit plans are provided on actuarial basis for the Company as a whole, the amount pertaining to key managerial personnel are not included.

# C. Related party transaction other than those with key management personnel

|   | Transaction value | Balance                        |
|---|-------------------|--------------------------------|
|   | Half Year ended   | Half Year ended<br>30 Sep 2020 |
|   | 30 Sep 2020       |                                |
| Outlab processing charges paid / payable              |                   |                                |
| Equinox Labs Private Limited                          |                   | 0.03                           |
| Payment of lease liabilities                          |                   |                                |
| Sumathi Healthcare Private Limited *                  | 0.32              | -                              |
| Loan taken from                                       |                   |                                |
| Pavilion Commercial Private Limited                   | -                 | 2.50                           |
| Interest paid   |                   |                                |
| Pavilion Commercial Private Limited                   | 0.11              | 0.11                           |
| Revenue from operations                               |                   |                                |
| Thyrocare Gulf Laboratories WLL                       | 0.04              | 2.09                           |
| Sumathi Memorial Trust (refer note)                   | 0.04              | 0.02                           |
| Reimbursement of expenses paid                        |                   |                                |
| Sumathi Healthcare Private Limited *                  | 0.34              | 0.24                           |
| Technical assistance fees income                      |                   |                                |
| Thyrocare Gulf Laboratories WLL                       | 0.67              | 3.76                           |
| Advances received towards sale of property            |                   |                                |
| Sumathi Healthcare Private Limited *                  | -                 | 25.00                          |
| Investment in equity instruments (At historical cost) |                   |                                |
| Equinox Labs Private Limited                          |                   | 20.00                          |
| Security deposits given/ (repaid)                     |                   |                                |
| Sumathi Healthcare Private Limited *                  | -                 | 1.54                           |

\* Formerly known as Sumathi Construction Private Limited



# Thyrocare Technologies Limited

# Notes to the consolidated financial statements

for the half year ended 30 Sep 2020

### Currency : In crore of INR

## Notes :

- i. The key management personnel, or their related parties, hold position in other entities that result in them having control or significant influence over these entities. These entities transacted with the Company during the reporting period. The terms and conditions of the transactions with key management personnel and their related parties were at arm's length and in the normal course of the business.
- ii. Sumathi Memorial Trust, a charitable trust managed by the promoters of the Company as trustees, in tie up with other NGO subsidised the cost of PET-CT scans for the cancer patients who can not afford the cost of the PET-CT scan, by direct payment to the Company cost of PET-CT scans towards such cancer patients.

